FusionPharm, Inc.
FusionPharm, Inc. (FSPM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
fspm · pe ratio · data through Jun 8, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
FusionPharm, Inc.You FSPM | $0M | N/A | — | — |
 Adynxx, Inc. ADYX | $0M | N/A | — | -$10.26 |
 BG Medicine, Inc. BGMD | $0M | N/A | — | -$0.55 |
 BIMI International Medical Inc. BIMI | $0M | N/A | — | -$8.40 |
 Bionik Laboratories Corp. BNKL | $0M | N/A | — | -$0.72 |
 ContraFect Corporation CFRXQ | $0M | N/A | — | -$124.97 |
 Grupo International Inc. GRPI | $0M | N/A | — | -$0.01 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for FusionPharm, Inc. (FSPM) measures how much investors pay for each dollar of the company's trailing earnings. FSPM's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
FSPM pe ratio · 6 questionsFSPM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via FSPM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · FusionPharm, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08